Closed Solicitation · DEPT OF DEFENSE
AI Summary
The Department of Defense is seeking industry collaboration to develop and manufacture an analgesic ketamine product for battlefield use. This RFI addresses the requirement for Tactical Combat Casualty Care solutions for severe pain management. Various formulations, including autoinjectors and topical applications, will be considered. A request for proposals is anticipated in Fiscal Year 2026.
The purpose of this RFI is to address the OPMED WPAC PMOs requirement for Tactical Combat Casualty Care (TCCC) solutions for acute severe pain from battlefield injuries. The OPMED WPAC PMO is conducting market research to determine the feasibility to collaborate with industry to develop, manufacturer, and receive U.S. Food and Drug Administration (FDA) approval of an analgesic ketamine product for procurement. All ketamine products for any route of administration will be considered, for example: autoinjectors, oral capsules, pumps, topical creams and patches, etc. OPMED WPAC PMO plans to release a request for proposals for the analgesic ketamine product in Fiscal Year 2026. Please see list of attachments for other instructions.
Analgesic Ketamine for Battlefield Use is a federal acquisition solicitation issued by DEPT OF DEFENSE. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.
SamSearch Platform
AI-powered intelligence for the right opportunities, the right leads, and the right time.